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Abstract 
Congenital myopathies define a heterogeneous group of neuromuscular diseases with neonatal 
or childhood hypotonia and muscle weakness. The genetic cause is still unknown in many 
patients, precluding genetic counseling and better understanding of the physiopathology. To 
identify novel genetic causes of congenital myopathies, exome sequencing was performed in 
three consanguineous families. We identified two homozygous frameshift mutations and a 
homozygous nonsense mutation in the mitogen-activated protein triple kinase ZAK. In total 
six affected patients carry these mutations. RT-PCR and transcriptome analyses suggested 
nonsense mRNA decay as a main impact of mutations. The patients demonstrated a 
generalized slowly progressive muscle weakness accompanied by decreased vital capacities. 
A combination of proximal contractures with distal joint hyperlaxity is a distinct feature in 
one family. Common histopathological features encompassed fiber size variation, 
predominance of type 1 fiber and centralized nuclei. A peculiar subsarcolemmal accumulation 
of mitochondria pointing towards the center of the fiber was a novel histological hallmark in 
one family. These findings will improve the molecular diagnosis of congenital myopathies 
and implicate the mitogen-activated protein kinase (MAPK) signaling as a novel pathway 
altered in these rare myopathies. 
 
 
Keywords  
Congenital myopathy, centronuclear myopathy, hyperlaxity, exome, kinase 
 
Abbreviations 
CM = congenital myopathy; CNM = centronuclear myopathy; DMD = Duchenne muscular 
dystrophy ; ES = exome sequencing; FDR= False discovery rate; LGMD = Limb-girdle 
muscular dystrophy; MAF = Minor allele frequency; MAPK = mitogen-activated protein 
kinase; MDC1A = Limb-girdle muscular dystrophy 1A; RPKM= reads per kilobase per 
million mapped reads; UCMD = Ullrich muscular dystrophy; XLMTM = X-linked 
myotubular myopathy; ZAK = mitogen-activated protein triple kinase or sterile alpha motif 
and leucine zipper containing kinase; 
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Introduction 
Congenital myopathies (CM) form a heterogeneous group of genetic muscle diseases 
characterized by congenital or early childhood hypotonia, muscle weakness and structural 
abnormalities in muscle biopsies (Nance et al., 2012). CMs are accompanied by chronic long-
term disability, a strong decrease in the quality of life and a shorter lifespan (North et al., 
2014). They are sub-classified in seven distinct types based on clinical presentation and 
characteristic features on biopsy. Main classes encompass nemaline myopathies with protein 
aggregates, core myopathies with well-defined muscle fiber areas devoid of oxidative activity, 
centronuclear myopathy with predominance of fibers with internal and centralized nuclei, and 
congenital fiber type disproportion with a bias toward smaller and more abundant type 1 
fibers (North et al., 2014). Extensive studies of large families and cohorts led to the 
identification of approximately 30 genes (www.orpha.net) mutated in CMs; this number is 
even higher when considering the overlap with congenital muscular dystrophies (Bonnemann 
et al., 2014). Despite these advances, nearly half of patients still have no molecular diagnosis 
(Amburgey et al., 2011). This is due to the extensive clinical and genetic heterogeneity and to 
the limitation of gene-by-gene diagnostic sequencing. Therefore, each uncovered novel CM 
gene probably explains an increasingly smaller subset of remaining unsolved patients. The use 
of next-generation sequencing (NGS) methods, such as gene panels or exome sequencing 
(ES), will overcome some of the diagnostic challenges and help uncover novel CM genes 
(Tetreault et al., 2015). The identification of the disease-causing gene allows a better care and 
prognosis for the patients, and a more accurate genetic counseling (Vasli and Laporte, 2013). 
Moreover, the identification of novel implicated genes lead to underlying pathological 
mechanisms, and highlights novel targets that may be more amenable for the development of 
treatments. 
In this study, in an effort to identify additional genes implicated in congenital 
myopathies, three consanguineous families, from different ethnic backgrounds, were exome 
sequenced independently and were found to carry different homozygote mutations in the 
mitogen-activated protein triple kinase ZAK. 
 
 
Material and methods 
Patients 
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One patient originated from France (Family 1), two affected siblings from Quebec (Family 2) 
and three affected siblings from the UK (Family 3) were recruited independently. All patients 
and family members underwent a detailed neurological examination by experienced 
neurologists. Sample collection was performed with written informed consent from the 
patients and all participating family members, according to the declaration of Helsinki. 
Genomic DNA was extracted from peripheral blood lymphocytes using standard procedures. 
 
Histology 
Left deltoid muscle for patient I-1 and deltoid muscle for patient II-1 were analyzed. For 
conventional histochemical techniques 10 µm thick cryostat sections were stained with 
haematoxylin and eosin (H&E), modified Gomori trichrome (mGT), Periodic acid Schiff 
technique (PAS), Oil red O, reduced nicotinamide adenine dinucleotide dehydrogenase-
tetrazolium reductase (NADH-TR), succinate dehydrogenase (SDH), cytochrome c oxidase 
(COX), and adenosine triphosphatase (ATPase) preincubated at pH 9.4, 4.63, 4.35 and 
examined with a Zeiss Axioplan Bright Field Microscope and photos processed with the Axio 
Vision 4.4 software (Zeiss, Germany) (Malfatti et al., 2015). The fibre type pattern was 
determined by counting 1000 fibres from each patient in ATPase 9.4 and 4.35 reactions, and 
by calculating the percentage of type 1 and type 2 fibres. 
 
Electron microscopy 
Muscle specimens were fixed with glutaraldehyde (2.5%, pH 7.4), post fixed with osmium 
tetroxide (2%), dehydrated and embedded in resin (EMBed-812, Electron Microscopy 
Sciences, USA). Ultra-thin sections were stained with uranyl acetate and lead citrate. The 
grids were observed using a Philips CM120 electron microscope (80 kV; Philips Electronics 
NV, Eindhoven, The Netherlands). 
 
Genetic analyses  
Family 1 
MTM1, BIN1 and DNM2 were excluded for I-1 by Sanger sequencing of exons and intron-
exon boundaries. MTM1 level was normal by Western blot analysis. RYR1 was excluded by 
cDNA sequencing from muscle, while no pathogenic variant was found in TTN in the ES 
analysis.  
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Homozygosity-by-descent analysis was performed after hybridization of fragmented 
genomic DNA on Affymetrix genomewide human SNP 6.0 arrays, following the 
manufacturer’s protocols (www.affymetrix.com). 
 
Family 2 
Genotyping analysis of microsatellite markers allowed us to exclude COL6A1 and COL6A2. 
Due to lack of informative markers in close proximity to COL6A3 we excluded the presence 
of mutations in this gene by sequencing all exon and exon-intron boundaries of the genomic 
DNA and the entire cDNA (Tetreault et al., 2006). 
Homozygosity mapping was performed using the Illumina OmniExpress SNPs chip 
(700K markers). Homozygous regions larger than 1Mb shared by both affected, heterozygous 
in parents and unaffected sibling were identified using Genome Studio (Illumina, California, 
USA) and AutoSNPa (Carr et al., 2006). 
 
Family 3 
Direct sequencing of FKRP, DYSF and CAPN3 and copy number analysis of SMN1 excluded 
pathogenic mutation of these genes in III-1. Haplotype analysis of all known LGMD loci in 
2010 was performed in patients III-1 and III-2, which excluded most loci, but was compatible 
with possible linkage to the loci encompassing DYSF (excluded by sequencing) and TTN (no 
putative pathogenic variants later identified by ES).   
 
Exome sequencing 
Exome sequencing was performed on affected sibling and parents of family 1, both affected 
siblings and the mother of family 2, and on two of the three affected siblings (patients III-1 
and III-2) in family 3. ES for family 1 was performed at BGI (China). ES for family 2 was 
performed at Perkin Elmer sequencing service center (Perkin Elmer, USA). ES for family 3 
was performed by deCODE genetics (Iceland). Fragmented genomic DNA was enriched with 
the Agilent SureSelect Human all Exon 50Mb capture library (v4) and sequenced 90nt paired-
end on Illumina HiSeq2000 sequencer. Patient I-1 was also sequenced at CNG (Evry) 
following targeted enrichment on a custom library of 2500 genes including genes implicated 
in neuromuscular diseases and functional candidate genes for congenital myopathies based on 
data mining. Alignment to the reference genome was done with BWA or SOAP and variant 
calling with Samtools, SVA or GATK (Bao et al., 2011). Common variants (> 1%) found in 
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dbSNP, 1000 genomes, Exome Variant Server, and internal exome databases were filtered 
out. Non-synonymous variants predicted to be damaging, putative splicing variants and 
coding indel found homozygous in affected and heterozygous in parents were selected, based 
on the known consanguinity of the families. Truncating variants in the ZAK gene 
(NM_133646) were identified in all sequencing experiments and in all three families and their 
presence and segregation confirmed by Sanger sequencing (primers in Supplementary Table 
1; exome coverage metrics in Supplementary Table 2). 
 
RNA studies 
RNA-seq was performed on RNA extracted from muscle tissue of patient II-1. TruSeq mRNA 
stranded library preparation was used and the sequencing was performed on an Illumina Hiseq 
2000 at McGill University and Genome Quebec Innovation Center (Montreal, Canada). The 
reads were aligned using STAR (Dobin et al., 2013). Read counts were obtained using 
Featurecounts (Liao et al., 2014) and expression data using DESeq (Love et al., 2014). To 
obtain differential expression, the counts were compared to muscle from two samples with 
normal muscle pathology. Fold change ≥ 2 for up-regulated and ≤ -2 for down-regulated with 
a p-value ≤ 0.05 was considered significant. Gene Ontology (GO) term and pathway 
enrichment analysis was performed using DAVID (https://david.ncifcrf.gov). The lists of up-
regulated and down-regulated genes were compared to a background list consisting of genes 
expressed in 11 muscles RNA-seq samples. Selected genes had a RPKM ≥ 1 (Mortazavi et al., 
2008) in more than five samples. For GO term, biological process, molecular function and 
cellular compartment were considered. Clusters with an enrichment score above 1.5 were 
considered significant. For KEGG analysis, pathways with a corrected Benjamini p-value ≤ 
0.05 and a % FDR > 20 were considered relevant (Paco et al., 2013). 
 
For RT-PCR, total RNA was extracted from cells and tissues with Tri-Reagent 
(Sigma), and cDNA was reverse transcribed using the SuperScript II Reverse Transcriptase 
(Invitrogen) and random hexamer primers. Real-time quantitative RT-PCR was performed 
using a Lightcycler 480 (Roche Diagnostics, Meylan, France) with the SYBR Green 1 Master 
kit (Roche Diagnostics); results were standardized to GAPDH and 18S. Primers for ZAK 
fragments are in Supplementary Table 1. 
 
Results 
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Clinical features 
Family 1 
The male patient from family 1 is French from Caucasian origin. Parents are first-degree 
cousins.  He was affected from 28mo and is presently aged 27yr (Table 1). Muscle weakness 
is proximal in upper limbs and diffuse, proximal and distal in lower limbs. Winged scapula is 
present. The patient can walk up to 200m, has difficulties climbing stairs and is not able to 
run. Fatigability and diurnal cramps are noted. Clinical examination did not reveal hyperlaxity 
or contractures. Hyperlordosis is present, and ventilatory capacity slightly decreased from 
85% at 17yr to 80% at 21yr. Apart from a slightly elongated face, no facial weakness, ptosis 
or ophtalmoplegia are present and tongue movement, speech and swallowing are normal. 
EMG was myopathic in the four limbs. Repetitive nerve stimulation showed a decrement of 
10% of the compound motor action potential. Cardiac examination by ECG and cardiac 
ultrasound was normal. CK was mildly elevated (777, 604, 1334U/l).  
 
Family 2 
Family 2 is of French-Canadian origin from the southwestern part of Quebec. Parents are third 
degree cousins and do not present any myopathy phenotype, although distal laxity is observed 
in parents and an unaffected sister. Age at diagnosis was 4yr and 2yr for female patients II-1 
and II-2. Patient II-1 passed away at age 37 and the youngest is now aged 33yr (Table 1) 
(Tetreault et al., 2006). They were hypotonic with contractures at birth. They demonstrated a 
generalized slowly progressive muscle weakness. Motor delay was observed in both patients, 
patient II-1 walked at 3 yr and patient II-2 at 17mo. Patient II-2 is still ambulant but patient II-
1 was wheelchair bound following a car accident and a period of prolonged immobilization at 
32yr. They both have hyperlaxity, cervical spine hypermotility and contractures; patient II-1 
showed elbow laxity and repetitive shoulder dislocation due to the hyperlaxity in combination 
with ankle and finger contractures. Patient II-1 also has a mild scoliosis, which did not 
necessitate any surgery. Vital capacity was decreased to 63% and 86% in patients II-1 and II-
2, respectively. Cardiac examination by ECG and ultrasound was normal, and there was no 
CNS involvement. CK level are normal for both siblings (32U/I for patients II-1 and 90U/I for 
patients II-2) (Table 1). 
 
Family 3 
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Family 3 is of British Pakistani origin. Parents are first-degree cousins and are unaffected. 
They have six offspring, of whom three are affected. Patient III-1 is female, and developed 
pain in her legs and walking difficulties at age 4-5 years, and was noted to have scoliosis at 
that time. Since then she experienced slowly progressive weakness. On examination at age 32 
years she had waddling gait, hyperlordosis, and prominent proximal lower limb with mild foot 
extensor weakness (Table 1). There was mild proximal upper limb weakness with scapular 
winging. There was no facial weakness, contractures or hyperlaxity. FVC was 98% in sitting 
and 86% in lying. Recent echocardiography and ECG were normal. CK was mildly elevated 
(439U/l). Patient III-2 is male and was noted to be floppy from birth with slow motor 
development. He had calf hypertrophy and pain in legs while walking in childhood. On 
examination at age 26 years he had striae, asymmetric calf hypertrophy, quadriceps wasting, a 
waddling gait and scapular winging (Table 1). CK was mild to moderately elevated (709-
1526U/l). Patient III-3 is male and was reported to have floppiness from birth and delayed 
motor development and scoliosis. He has proximal upper and lower limb weakness with calf 
hypertrophy and scapular winging. CK was normal to mildly elevated. 
 
Muscle pathology for the three families  
Affected cases from all families shared the histopathological features (Fig. 1) of fiber size 
variation with hypo and hypertrophic fibers and numerous rounded fibers. Type 1 fibers were 
very predominant and common to all patients; type 2 fibers were atrophic for patient II-1 (Fig. 
1F) and normal in size for patient I-1. Patients I-1 and II-1 also displayed regional 
replacement of fibers by adipocytes but no inflammatory infiltrate. Some split fibers were 
noted for patient I-1 (Fig. 1A-C), while an increase in endomysial connective tissue was 
specific for patient II-1 (Fig. 1D-E). Hyaline bodies were absent. The muscle biopsy of patient 
I-1 was classified as centronuclear myopathy with rimmed sarcolemma based on the 
predominance of fibers with central nuclei and abnormal accumulation of mitochondria at the 
periphery. Centralized and internalized nuclei were also a common feature for patient II-1, 
sometimes with clump of nuclei. The main difference between the biopsies was the presence 
of rimmed vacuoles (Fig. 1E) sometimes containing eosinophilic or basophilic masses in 
patient II-1, while fibers in patient I-1 had a spicular aspect due to the peculiar 
subsarcolemmal accumulation of mitochondria clearly noted on SDH staining (Fig. 1B). The 
presence of rimmed vacuoles was also an important feature in patient III-2 (Fig. 1G-H). Both 
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patients III-2 and III-3 had evidence of sarcoplasmic disorganization and patient III-2 also has 
accumulation of subsarcolemmal material, in keeping with findings in patient I-1 (Fig. 1I). 
 Electron microscopy analysis revealed that central nuclei are tightly surrounded by 
myofibrils but not by a halo of membranes and organelles as for classical centronuclear 
myopathies with mutations in MTM1, BIN1 or DNM2 (Fig. 1J). In patient I-1, it confirmed the 
spicular aspect is due to subsarcolemmal accumulations of mitochondria that point towards 
the center of the fiber, separating the myofibrils (Fig. 1K). In patient II-2, it showed the 
rimmed vacuoles contain whorls of cytomembranes, suggesting an autophagosomal origin 
(data not shown). 
 
Identification of recessive ZAK mutations 
In order to identify the genetic basis of this myopathy, NGS was performed on all families 
independently (Supplementary Table 2). Targeted sequencing of 2500 candidate genes 
followed by exome sequencing from patient I-1 and parents was performed. After filtering 
following a recessive inheritance mode of transmission based on family structure and known 
consanguinity, the only gene that displayed pathogenic variants on both alleles with the 
expected segregation was ZAK on chromosome 2q31.1, encoding for the sterile alpha motif 
and leucine zipper containing kinase (Fig. 2). ZAK mapped to one of the largest homozygous 
regions, based on DNA microarray analysis and confirmed by exome data (Supplementary 
Fig. 1A). For family 2, an exome approach was used on both affected siblings and their 
mother. After filtering for rare homozygous variants (<1% MAF), four candidate genes were 
identified: RHBG, TMEM177, ZAK and LOXHD1. All of these genes were present in a 
homozygous region previously identified by homozygosity mapping (Supplementary Fig. 
1B). Segregation analysis with the entire family allowed the exclusion of three of these genes, 
leaving ZAK as the only candidate. In family 3 patients III-1 and III-2 underwent ES and the 
resulting variants were filtered to include rare (<1% MAF) homozygous variants. SNP data 
extracted from ES was applied in Homozygosity Mapper to define regions of autozygosity 
(Supplementary Fig. 1C). Only two genes had rare homozygous variants and these were both 
within a region of autozygosity (ZAK, CAMK2D). Segregation analysis in patient III-3, both 
parents and one unaffected sibling excluded CAMK2D and confirmed ZAK as the only 
remaining candidate gene. Candidate ZAK homozygous variants were: a deletion 
c.490_491delAT in exon 7 leading to a frameshift and a predicted premature stop codon 
p.Met164fs*24 in patient I-1, a nonsense variants (c.515G>A; p.Trp172*) also in exon 7 in 
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cases II-1 and II-2, and a T insertion in exon 4 leading to a premature stop codon 
(c.280_281insT p.Asn95*) in siblings III-1, III-2 and III-3 (Fig. 2A-D). 
 The mutations were confirmed using Sanger sequencing, and parents were all 
heterozygous for the changes in accordance with a recessive inheritance. These mutations 
were not reported in dbSNP, 1000 genomes, NHLBI Exome Variant Server, or the ExAC 
database. In addition, we did not observe these variants in two internal French and Canadian 
exome databases (1550 and 2000 samples including ethnically matched individuals) and by 
Sanger sequencing of controls (200 French and 65 French-Canadians). Noteworthy, there are 
no homozygous nonsense or frameshift variants for the ZAK gene in any of these databases, 
supporting the notion that truncations or loss of function in this protein are deleterious. The 
sequencing of a cohort of 184 unrelated patients classified as centronuclear myopathy and 26 
French-Canadian patients affected by a congenital myopathy with hyperlaxity did not reveal 
additional mutations. 
ZAK, also called MLTK, MRK or MLK7, is a member of the mitogen-activated 
protein triple kinase (MAPKKK) family implicated in signal transduction and encompasses an 
N-terminal kinase domain encoded by exons 2 to 9, followed by dimerization domains: a 
leucine zipper motif and a sterile-alpha motif (SAM) (Fig. 2D) (Liu et al., 2000, Bloem et al., 
2001, Gotoh et al., 2001). An alternate splice isoform 2 differs in the 3’UTR and does not 
encode the SAM domain.  
Since all uncovered ZAK mutations are predicted to lead to loss of expression of the 
full-length protein we explored if RNA sequencing would give us some evidence to support 
mRNA decay.  To assess the impact of the variants on RNA level, transcriptome analysis on 
patient I-1 and II-1 were performed. Whole transcript microarrays of cells from patient I-1 
detected an important decrease in ZAK mRNA level (down to 43% of controls). This 
observation was confirmed by RT-PCR analysis using two different primer pairs (Fig. 3A). 
RNA sequencing on skeletal muscle of patient II-1 also demonstrated a significant decrease of 
ZAK (fold change -3.5 pvalue: 4.17E-10) compared to control samples (Fig. 3B). Western blot 
analysis on skeletal muscle proteins from patient III-2 showed a complete absence of the 52 
kDa band that corresponds to the shorter isoform 2 of ZAK in muscle (Fig. 3C) (Gross et al., 
2002). Together, these data strongly support nonsense mRNA decay as the main impact of 
ZAK mutations. 
 
Physiopathological insight 
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ZAK was previously reported to be expressed in different tissues with a higher expression in 
skeletal muscle and heart where the shorter isoform 2 is predominant (Liu et al., 2000, Bloem 
et al., 2001, Gotoh et al., 2001, Gross et al., 2002). Mining the GTEx database confirmed 
highest expression in skeletal muscle and bladder among 43 human tissues and the 
predominant presence of isoform 2 in skeletal muscle (Consortium, 2015). We used RT-PCR 
from different mouse tissues and differentiating mouse and human muscle cells in culture and 
found ZAK is expressed in several tissues, especially in type I skeletal muscles such as 
diaphragm and soleus, while it appeared more expressed in dividing myoblasts than 
differentiating myotubes (Fig. 3D-E). Together, these data support the importance of ZAK 
isoform 2 in skeletal muscle. 
 
We compared the transcriptome of patient II-1 muscle with two controls and identified 
a total 518 differentially expressed genes (124 down-regulated and 394 up-regulated) 
(Supplementary Table 3). GO enrichment analysis considering biological process, molecular 
function as well as cellular compartment was performed using DAVID and was consistent 
with analysis obtained for KEGG pathways (Table 2). Among the up-regulated GO terms and 
pathways and the most relevant to a muscle disease were cell adhesion, extracellular matrix 
(ECM), glycosaminoglycan/carbohydrate binding, muscle development, hypertrophic 
cardiomyopathy and dilated cardiomyopathy, enzyme receptor protein signaling, and TGF-
beta signaling. The main down-regulated categories were gluconeogenesis, glucose 
metabolism and insulin pathway, sarcomere protein, muscle development and differentiation, 
calcium and MAPK signaling pathway.  
 
A similar pattern of up and down regulated genes and pathways are observed in other 
muscle diseases, especially in Ullrich muscular dystrophy (UCMD) but also in Duchenne 
muscular dystrophy (DMD), Limb girdle muscular dystrophy 1A (MDC1A), X-linked 
myotubular myopathy (XLMTM) and others (Supplementary Table 3) (Noguchi et al., 2005, 
Saenz et al., 2008, Kotelnikova et al., 2012, Paco et al., 2013). MYH8, TNN2 and MYH3, 
involved in muscle contraction, regeneration and differentiation, are up-regulated in patient II-
1 as well as in UCMD patients (Paco et al., 2013). These genes are usually predominantly 
expressed in fetal skeletal muscles and could be associated with attempt to regenerate the 
damage muscle fibers. An increase expression of collagens and important ECM genes, 
including biglycan (BGN) and lumican (LUM), is also observed in UCMD and LGMD2A 
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patients for collagens (Saenz et al., 2008, Paco et al., 2013), and in UCMD, DMD and 
MDC1A patients for BGN and LUM. The expression level of BGN and LUM has been 
associated with the degree of fibrosis in DMD and MDC1A (Zanotti et al., 2005, Zanotti and 
Mora, 2006). This increase may be correlated to the infiltration of endomysial connective 
tissue and the increased fibrosis. In contrast to the increased expression of ECM genes, 
sarcomeric components of the actin cytoskeleton and Z-disc (ACTA1, ALDOA, CSRP3, 
FLNC, FHL3, MYOZ3, TTN and TCAP) show a lower expression when compared to controls. 
This observation was also previously reported in UCMD patients. Decrease expression of 
genes involved in the glycolytic pathway (PGM1, PGAM2 and FBP2) is also seen in DMD, 
nemaline myopathy and XLMTM (Noguchi et al., 2005) but is up-regulated in UCMD. It is 
also interesting to observe a decrease expression of the MAPK signaling pathway, since ZAK 
is a member of the MAPKKK family. The down-regulation of this pathway did not stand out 
in the transcriptome analysis performed on other muscle diseases and might thus be a more 
specific signature for ZAK myopathy. 
 
Discussion 
We have identified recessive mutations in the kinase ZAK as a novel cause of congenital 
myopathy. Different mutations were found in three unrelated families with overlapping 
phenotypes. The mutations were homozygous as suggested from the known consanguinity of 
the families, segregated as a recessive trait with the disease, caused a premature stop codon 
within the kinase domain at the N-terminus of the protein, and led to nonsense mRNA decay.  
 
Clinical and histological spectra 
Patients with ZAK mutations share a generalized slowly progressive muscle weakness of 
neonatal or childhood onset with a mild to moderate decrease in vital capacity (63-98% of 
predicated vital capacity). Developmental delay and scoliosis are also important clinical 
features of ZAK myopathy. Unlike other congenital myopathies such as centronuclear, core or 
nemaline myopathies, no prominent facial weakness is present. The presence of mild 
contractures with distal hyperlaxity is a major feature in family 2, but is not observed in the 
other families with the exception of patient III-2 for whom hyperlaxity was described. 
Inherited muscle diseases are known to have a high clinical heterogeneity, and genetic and 
environmental heterogeneity may link a single gene with variable clinical features, severity 
and age of onset (Cirak et al., 2013). We believe the patients in this study share sufficient 
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clinical and pathological features to support a common disease mechanism. Noteworthy, 
although patients of family 3 presented with a congenital/early childhood onset, they 
displayed a LGMD phenotype in adulthood, suggesting ZAK mutations as a cause of LGMD 
phenotype as well. At the histopathological level, all patient biopsies share fiber size variation 
and predominance of type 1, as in other CM. The presence of rimmed vacuoles and especially 
the spicular subsarcolemmal accumulation of mitochondria could be pathological feature 
useful to identify additional patients to be tested for ZAK mutations. Targeted or exome 
sequencing of a larger cohort of patients with myopathies will be needed to characterize the 
full clinical and pathological spectrum linked to ZAK mutations. Thus, ZAK represents an 
excellent novel candidate for patients with undefined congenital myopathies or LGMD and no 
genetic cause identified so far. 
  
Pathological mechanisms 
ZAK is a serine-threonine kinase that was implicated in the activation of the ERK, JNK and 
p38 pathways (Liu et al., 2000, Bloem et al., 2001, Gotoh et al., 2001, Christe et al., 2004). 
Overexpression in cultured cells induces apoptosis (Liu et al., 2000) and preliminary 
experiments in zebrafish confirmed that exogenous expression of ZAK is toxic (unpublished 
data) suggesting a tightly regulated level of ZAK is needed, consistent with its role in signal 
transduction. ZAK was also implicated in actin fiber modulation and in the TGF-beta-induced 
cardiomyocyte hypertrophy in vitro while ZAK overexpression in vivo induced cardiac 
hypertrophy (Christe et al., 2004, Huang et al., 2004, Hsieh et al., 2015). The link between 
ZAK and these different pathways is interesting since most are involved in myogenesis 
(Burks and Cohn, 2011). Signalization through the p38 pathway regulates muscle 
regeneration and causes the irreversible withdrawal from the cell cycle, which is necessary for 
the myoblasts differentiation. JNK pathway is known to act as a negative regulator of 
myogenesis, whereas ERK has many roles such as both enhancing myoblast proliferation and 
repressing their differentiation. A possible role of ZAK in muscle regeneration is in 
concordance with the variable muscle fiber size and the presence of central nuclei observed 
on the muscle biopsies.  
 Our pathological data supports that loss of ZAK in human leads to fiber size variation 
and type 1 predominance as well as accumulation of mitochondria at the periphery fibers in 
some cases. In vitro assays have shown that ZAK isoform 2 (also known as MRK-beta) 
preferentially activates the p38γ/ERK6 pathway via MKK3/MKK6 (Gross et al., 2002). 
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Moreover, p38γ is constitutively activated in type I skeletal muscle but not in type II fibers 
muscle and a p38γ KO shows specific reduction of slow muscle size over time, indicating a 
role for p38γ in slow muscle growth (Foster et al., 2012). Interestingly, the number of type I 
fibers was significantly increased in soleus from p38γ KO mice (Foster et al., 2012). Thus, it 
is plausible that disruption of this MAPKKK cascade underlies the predominance of type I 
fibers observed in patients.  
 Recently, mutations in ZAK were identified in patients affected by development limb 
defects. Spielmann et al. reported a missense variant (Phe368Cys) and an in-frame deletion 
both in the SAM domain, which is only present in the longer ZAK isoform 1 (Fig. 2D) 
(Spielmann et al., 2016). The six patients reported in our study carry truncating mutations in 
the kinase domain and have a distinct phenotype with no split-foot abnormality. This suggests 
that limb defects are specifically due to variants present in the SAM domain without loss of 
ZAK. The mutated long isoform of ZAK could potentially act as a dominant negative 
resulting in a down-regulation of Trp63 in the limb bud (Spielmann et al., 2016). The 
complete inactivation of ZAK seems to have a more severe effect in mice, since the knockout 
mouse was reported to be embryonic lethal due to severe cardiac edema and growth 
retardation (Spielmann et al., 2016).  In contrast, we are reporting six patients with null 
mutations in ZAK and presenting a myopathy phenotype. Though we have no evidence for 
this apparent species difference, it maybe that ZAK is more essential for normal 
developmental in mice than in Human. 
 Transcriptome analysis from muscle of one ZAK patient showed similarities with 
other muscle diseases, in particular congenital myopathies such as UCMD with up-regulation 
of ECM components as well as a down-regulation of sarcomeric genes and down-regulation 
of gluconeogenesis as in XLMTM. Up-regulation of ECM genes seems to be common to 
many dystrophic processes and is potentially an indication of signal transduction defects. 
While alteration in the regulation of signal transduction can have a wide cellular impact, 
future studies will be needed to identify the precise role of ZAK and its specific substrates in 
skeletal muscle and to decipher the molecular cascade of events leading to the associated 
myopathy. 
 
 
Web resources 
Gene table of neuromuscular disorders: www.musclegenetable.fr 
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1000 genomes: www.1000genomes.org 
NHLBI exome variant server: evs.gs.washington.edu/EVS 
dbSNP: www.ncbi.nlm.nih.gov/SNP 
Affymetrix: www.affymetrix.com 
Illumina: www.illumina.com 
AutoSNPa: http://dna.leeds.ac.uk/autosnpa/) 
ExAC Browser: http://exac.broadinstitute.org  
GTEx: http://www.gtexportal.org/home/ 
 
 
Conflict of interest 
None of the authors reports conflicts of interest. 
 
 
Acknowledgements 
We would like to thank the families who participated in this study. We thank Claudia Strafella 
and Nicolas Haumesser for technical assistance, Nicole Monnier for RYR1 testing, BGI-
Shenzhen and Gabor Gyapay at CNG-Evry for sequencing. We also thank Edward Szekeres, 
from Perkin Elmer, for the bioinformatics support and Dr Paul Maddison for his assistance 
with family 3.  
 
 
Funding 
This work was supported by the Institut National de la Santé et de la Recherche Médicale 
(INSERM), Centre National de la Recherche Scientifique (CNRS), University of 
Strasbourg, Collège de France, Agence Nationale de la Recherche (ANR-11-BSV1-026), 
Fondation maladies rares, Association française contre les Myopathies (AFM-15352), 
Muscular Dystrophy Association (MDA-186985, MDA-113959, MDA-4075) and 
Myotubular Trust. The study was also supported by the Medical Research Council UK 
(reference G1002274, grant ID 98482), by the European Union Seventh Framework 
Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and 305121 
(Neuromics) to HL, Fondation GO. MT received a post-doctoral fellowship from the CIHR. 
 
Page 17 of 52
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
17 
 
 
References 
 
 
Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. Prevalence 
of congenital myopathies in a representative pediatric united states population. Annals 
of neurology 2011; 70:662-665. 
Bao S, Jiang R, Kwan W, Wang B, Ma X, Song YQ. Evaluation of next-generation 
sequencing software in mapping and assembly. J Hum Genet 2011; 56:406-414. 
Bloem LJ, Pickard TR, Acton S, Donoghue M, Beavis RC, Knierman MD, et al. Tissue 
distribution and functional expression of a cDNA encoding a novel mixed lineage 
kinase. J Mol Cell Cardiol 2001; 33:1739-1750. 
Bonnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, et al. 
Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord 
2014; 24:289-311. 
Burks TN, Cohn RD. Role of TGF-beta signaling in inherited and acquired myopathies. 
Skelet Muscle 2011; 1:19. 
Carr IM, Flintoff KJ, Taylor GR, Markham AF, Bonthron DT. Interactive visual analysis of 
SNP data for rapid autozygosity mapping in consanguineous families. Human 
mutation 2006; 27:1041-1046. 
Christe M, Jin N, Wang X, Gould KE, Iversen PW, Yu X, et al. Transgenic mice with 
cardiac-specific over-expression of MLK7 have increased mortality when exposed to 
chronic beta-adrenergic stimulation. J Mol Cell Cardiol 2004; 37:705-715. 
Cirak S, Foley AR, Herrmann R, Willer T, Yau S, Stevens E, et al. ISPD gene mutations are a 
common cause of congenital and limb-girdle muscular dystrophies. Brain : a journal of 
neurology 2013; 136:269-281. 
Consortium GT. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: 
multitissue gene regulation in humans. Science 2015; 348:648-660. 
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast 
universal RNA-seq aligner. Bioinformatics 2013; 29:15-21. 
Foster WH, Tidball JG, Wang Y. p38gamma activity is required for maintenance of slow 
skeletal muscle size. Muscle Nerve 2012; 45:266-273. 
Page 18 of 52
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
18 
 
Gotoh I, Adachi M, Nishida E. Identification and characterization of a novel MAP kinase 
kinase kinase, MLTK. J Biol Chem 2001; 276:4276-4286. 
Gross EA, Callow MG, Waldbaum L, Thomas S, Ruggieri R. MRK, a mixed lineage kinase-
related molecule that plays a role in gamma-radiation-induced cell cycle arrest. J Biol 
Chem 2002; 277:13873-13882. 
Hsieh YL, Tsai YL, Shibu MA, Su CC, Chung LC, Pai P, et al. ZAK induces cardiomyocyte 
hypertrophy and brain natriuretic peptide expression via p38/JNK signaling and 
GATA4/c-Jun transcriptional factor activation. Mol Cell Biochem 2015; 405:1-9. 
Huang CY, Chueh PJ, Tseng CT, Liu KY, Tsai HY, Kuo WW, et al. ZAK re-programs atrial 
natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast 
cells. Biochem Biophys Res Commun 2004; 324:973-980. 
Kotelnikova E, Shkrob MA, Pyatnitskiy MA, Ferlini A, Daraselia N. Novel approach to meta-
analysis of microarray datasets reveals muscle remodeling-related drug targets and 
biomarkers in Duchenne muscular dystrophy. PLoS Comput Biol 2012; 8:e1002365. 
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning 
sequence reads to genomic features. Bioinformatics 2014; 30:923-930. 
Liu TC, Huang CJ, Chu YC, Wei CC, Chou CC, Chou MY, et al. Cloning and expression of 
ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-
alpha motif. Biochem Biophys Res Commun 2000; 274:811-816. 
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
seq data with DESeq2. Genome Biol 2014; 15:550. 
Malfatti E, Monges S, Lehtokari VL, Schaeffer U, Abath Neto O, Kiiski K, et al. Bilateral 
foot-drop as predominant symptom in nebulin (NEB) gene related "core-rod" 
congenital myopathy. Eur J Med Genet 2015; 58:556-561. 
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying 
mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5:621-628. 
Nance JR, Dowling JJ, Gibbs EM, Bonnemann CG. Congenital myopathies: an update. Curr 
Neurol Neurosci Rep 2012; 12:165-174. 
Noguchi S, Fujita M, Murayama K, Kurokawa R, Nishino I. Gene expression analyses in X-
linked myotubular myopathy. Neurology 2005; 65:732-737. 
North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the 
diagnosis of congenital myopathies. Neuromuscul Disord 2014; 24:97-116. 
Page 19 of 52
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
19 
 
Paco S, Kalko SG, Jou C, Rodriguez MA, Corbera J, Muntoni F, et al. Gene expression 
profiling identifies molecular pathways associated with collagen VI deficiency and 
provides novel therapeutic targets. PLoS One 2013; 8:e77430. 
Saenz A, Azpitarte M, Armananzas R, Leturcq F, Alzualde A, Inza I, et al. Gene expression 
profiling in limb-girdle muscular dystrophy 2A. PLoS One 2008; 3:e3750. 
Spielmann M, Kakar N, Tayebi N, Leettola C, Nurnberg G, Sowada N, et al. Exome 
sequencing and CRISPR/Cas genome editing identify mutations of ZAK as a cause of 
limb defects in humans and mice. Genome Res 2016; 26:183-191. 
Tetreault M, Bareke E, Nadaf J, Alirezaie N, Majewski J. Whole-exome sequencing as a 
diagnostic tool: current challenges and future opportunities. Expert Rev Mol Diagn 
2015; 15:749-760. 
Tetreault M, Duquette A, Thiffault I, Bherer C, Jarry J, Loisel L, et al. A new form of 
congenital muscular dystrophy with joint hyperlaxity maps to 3p23-21. Brain : a 
journal of neurology 2006; 129:2077-2084. 
Vasli N, Laporte J. Impacts of massively parallel sequencing for genetic diagnosis of 
neuromuscular disorders. Acta Neuropathol 2013; 125:173-185. 
Zanotti S, Mora M. Proteoglycans are differentially altered in muscular dystrophies. 
ScientificWorldJournal 2006; 6:446-448. 
Zanotti S, Negri T, Cappelletti C, Bernasconi P, Canioni E, Di Blasi C, et al. Decorin and 
biglycan expression is differentially altered in several muscular dystrophies. Brain : a 
journal of neurology 2005; 128:2546-2555. 
Tables  
 
Table 1: Summary of the main clinical, histological and molecular features 
 
Table 2:  GO terms and KEGG pathways enrichment.  
 
Figure legends 
 
Figure 1: Muscle pathology. (A-C) HE, SDH and Gomori trichrome staining from patient I-1 
muscle biopsy. Arrows point to centralized nuclei and arrowheads to subsarcolemmal 
accumulation of mitochondria. (D-F) Muscle pathology from patient II-1 biopsy. (D) Islands 
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of muscle fibers are lost and replaced by adipocytes. (E) Scattered atrophic or rounded fibers 
are mixed with normal sized and hypertrophied fibers. Several muscle fibers (arrows) have 
typical rimmed vacuoles. Endomysial connective tissue is increased in some areas. A few 
muscle fibers have centrally situated myonuclei. (H&E 350x). (F) The vast majority of 
muscle fibers are of histochemical type I. The remaining few type II fibers are atrophic. 
(Myofibrillar ATPase, preincubation pH 10.2; 350x). (G-I) Muscle pathology from patient 
III-2 biopsy. (G) Muscle fibers with linear cracks and rimmed vacuoles. When displaced, 
nuclei tend to be in a central position. (H) Scattered fibers with multiple nuclei. (I) Numerous 
ring fibers (Desmin staining). (J-K) Electron microscopy on patient I-1 biopsy. (J) 
Ultrastructure of a central nucleus tightly surrounded by myofibrils. (K) Peculiar 
subsarcolemmal accumulation of mitochondria pointing inside the fibers.   
 
Figure 2: Genetic analysis and identification of ZAK mutations. (A-C) Pedigrees of the three 
families and chromatopherograms showing the mutations observed in each family, in relation 
to the reference sequence NM_133646. Black symbol indicates affected individuals and the 
dot indicates heterozygous carriers. (A) Family 1 (B) Family 2, (C) Family 3. (D) The ZAK 
protein encompasses a kinase domain (aa 16-277) with an ATP binding site (aa 45), a proton 
acceptor site (aa 133) and autophosphorylation sites (aa 161, 165), a leucine zipper (LZ; aa 
287-308), and a sterile alpha motif (SAM; aa 336-410 in isoform 1. Two isoforms (iso 1 and 
iso 2) are known and differ in their C-terminus. Red arrows indicate positions of the 
frameshift in family 1, the nonsense in family 2 and the frameshift in family 3. Blue arrows 
indicate the positions of mutations linked to limb defects and reported in Spielmann et al 
(Spielmann et al., 2016) 
 
Figure 3: ZAK expression and impact of mutations. (A) RT-PCR from patient I-1 (P1) and 
control cells with primers amplifying exons 3 to 11 (ZAK_a) or 9 to 11 (ZAK_b). GAPDH 
and 18S were used as housekeeping gene controls. (B) Gene reads counts from RNA-seq data 
on muscle biopsies from patient II-1 and two control samples. (C) Western blot analysis of 
muscle extract from patient III-2 with an anti-ZAK antibody. (D) Comparative RT-PCR 
analysis of different mouse tissues. GAPDH was used as a housekeeping gene control to 
normalize the values, which are displayed as a ratio compare to quadriceps. (E) Comparative 
RT-PCR analysis of mouse and human myoblasts and myotubes from 0 to 13 days of in vitro 
differentiation. GAPDH was used as a housekeeping gene control to normalize the values, 
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which are displayed as a ratio compare to mouse C2C12 muscle cells at 3d. Error bars 
represent s.e.m. 
 
Page 22 of 52
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
22 
 
 
Supplementary materials 
Supplementary Table 1: Primer sequences for amplification of genomic DNA or coding DNA. 
Supplementary Table 2: Exome coverage metrics. 
Supplementary Table 3: List of genes representing significant changes in expression in patient 
II-1.  
 
Supplementary Figure 1: Homozygosity-by-descent mapping in the three families. A) 
Family 1, the largest homozygous regions are listed based on the microarrays analysis and the 
interval and size are based on the exome data that confirmed their homozygosity (hg19 
release). B) Family 2, largest homozygous regions and size are based on SNPs array. ZAK is 
contained in the 2q31 homozygous region. C) Family 3, the homozygous region identified 
using Homozygosity Mapper and based on exome data.  
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Figure 1: Muscle pathology. (A-C) HE, SDH and Gomori trichrome staining from patient I-1 muscle biopsy. 
Arrows point to centralized nuclei and arrowheads to subsarcolemmal accumulation of mitochondria. (D-F) 
Muscle pathology from patient II-1 biopsy. (D) Islands of muscle fibers are lost and replaced by adipocytes. 
(E) Scattered atrophic or rounded fibers are mixed with normal sized and hypertrophied fibers. Several 
muscle fibers (arrows) have typical rimmed vacuoles. Endomysial connective tissue is increased in some 
areas. A few muscle fibers have centrally situated myonuclei. (H&E 350x). (F) The vast majority of muscle 
fibers are of histochemical type I. The remaining few type II fibers are atrophic. (Myofibrillar ATPase, 
preincubation pH 10.2; 350x). (G-I) Muscle pathology from patient III-2 biopsy. (G) Muscle fibers with linear 
cracks and rimmed vacuoles. When displaced, nuclei tend to be in a central position. (H) Scattered fibers 
with multiple nuclei. (I) Numerous ring fibers (Desmin staining). (J-K) Electron microscopy on patient I-1 
biopsy. (J) Ultrastructure of a central nucleus tightly surrounded by myofibrils. (K) Peculiar subsarcolemmal 
accumulation of mitochondria pointing inside the fibers.    
254x338mm (72 x 72 DPI)  
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Genetic analysis and identification of ZAK mutations. (A-C) Pedigrees of the three families and 
chromatopherograms showing the mutations observed in each family, in relation to the reference sequence 
NM_133646. Black symbol indicates affected individuals and the dot indicates heterozygous carriers. (A) 
Family 1 (B) Family 2, (C) Family 3. (D) The ZAK protein encompasses a kinase domain (aa 16-277) with an 
ATP binding site (aa 45), a proton acceptor site (aa 133) and autophosphorylation sites (aa 161, 165), a 
leucine zipper (LZ; aa 287-308), and a sterile alpha motif (SAM; aa 336-410 in isoform 1. Two isoforms (iso 
1 and iso 2) are known and differ in their C-terminus. Red arrows indicate positions of the frameshift in 
family 1, the nonsense in family 2 and the frameshift in family 3. Blue arrows indicate the positions of 
mutations linked to limb defects and reported in Spielmann et al (Spielmann et al., 2016)  
190x254mm (96 x 96 DPI)  
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ZAK expression and impact of mutations. (A) RT-PCR from patient I-1 (P1) and control cells with primers 
amplifying exons 3 to 11 (ZAK_a) or 9 to 11 (ZAK_b). GAPDH and 18S were used as housekeeping gene 
controls. (B) Gene reads counts from RNA-seq data on muscle biopsies from patient II-1 and two control 
samples. (C) Western blot analysis of muscle extract from patient III-2 with an anti-ZAK antibody. (D) 
Comparative RT-PCR analysis of different mouse tissues. GAPDH was used as a housekeeping gene control 
to normalize the values, which are displayed as a ratio compare to quadriceps. (E) Comparative RT-PCR 
analysis of mouse and human myoblasts and myotubes from 0 to 13 days of in vitro differentiation. GAPDH 
was used as a housekeeping gene control to normalize the values, which are displayed as a ratio compare to 
mouse C2C12 muscle cells at 3d. Error bars represent s.e.m.  
190x254mm (96 x 96 DPI)  
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Table 1. Summary of clinical, histopathological and 
molecular features 
   
 Patient I-1 Patient 
II-1 
Patient 
II-2 
Patient III-1 Patient III-2 Patient III-3 
Origin French 
caucasian 
French 
Canadian 
French 
Canadia
n 
British 
Pakistani 
British 
Pakistani 
British 
Pakistani 
       
Clinic       
Age at 
diagnosis 
28mo 4 yrs 2 yrs 4-5 yrs 
(floppy baby 
and delayed 
motor 
development
) 
2 yrs (floppy 
baby and 
delayed 
motor 
development
) 
early 
childhood 
(floppy baby 
and delayed 
motor 
development
) 
Muscle 
atrophy  
proximal and 
distal muscles  
thighs thighs thighs quadriceps  
Muscle 
weakness 
proximal and 
distal, upper 
and lower 
limbs 
 +  + proximal 
weakness, 
upper and 
lower limbs 
proximal and 
distal 
weakness 
lower limbs 
proximal 
weakness 
lower limbs 
(waddling 
gait) 
Joint laxity  -  ++ 
(elbow, 
shoulder) 
 ++  -  +  - 
Contractures  -  + (finger, 
ankle) 
 -  -  -  - 
Scoliosis  +  +  +  +  +  + 
calf 
hypertrophy 
 -  -  -  +  +  + 
Vital capacity 85% (2004); 
80% (2008) 
63% 86% 98% (sitting); 
86% (lying) 
 -  - 
facial 
weakness, 
ptosis 
 -  -  -  -  -  - 
EMG myopathic myopathi
c 
 - myopathic myopathic 
with 
spontaneous 
activity  
normal 
ECG, cardiac 
ultrasound 
normal   normal   normal   normal    -  - 
CPK 777-604-1334 
U/l 
normal(3
2 U/I) 
normal 
(90 U/I) 
360 - 439 u/l 709-1526 u/l normal / 
mildly 
elevated  
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Histology   no 
biopsy 
no biopsy   
Endomysial 
connective 
tissue 
normal   increased   increased normal 
Fiber size 
variation 
 ++  +    ++  + 
Rounded 
fibers 
 +  +    ++  + 
Type 1 
predominance 
 ++  ++    +  ++ 
Splitted fibers  +  -    -  - 
Central nuclei  ++  +    +  + 
Rimmed 
vacuoles 
 -  ++     +  - 
Sarcoplasmic 
disorganisatio
n 
 +  -    +  + 
Subsarcolemm
a material 
 ++  -    +  - 
       
Genetic       
ZAK mutation 
(nt) 
NM_133646 
c.490_491delA
T 
c.515G>A c.515G>
A 
c.280_281ins
T 
c.280_281ins
T 
c.280_281ins
T 
Predicted 
effect on 
protein 
p.Met164fs*2
4 
p.Trp72* p.Trp72* p.Asn95* p.Asn95* p.Asn95* 
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Table 2: GO terms and KEGG pathways enrichment 
  
    UP-REGULATED       
GO-Terms Enrichment scores     
cell adhesion 14.95     
extracellular matrix 13.16     
glycosaminoglycan binding 6.3     
plasma membrane 5.23     
skeletal development 4.62     
Enzyme receptor signaling pathway 3.91     
collagen - skin development 3.81     
ion binding 3.58     
cell-cell signaling 3.35     
muscle development 2.59     
muscle contraction process 2.45     
proteoglycan binding 2.39     
response to wounding 2.25     
KEGG Pathways Number of genes p-value FDR 
ECM-receptor interaction 7 1.29E-08 2.00E-07 
Focal adhesion 8 1.66E--07 5.15E-06 
Cell adhesion molecules 6 9.98E-07 4.64E-05 
Complement and coagulation cascades 5 4.40E-06 2.73E-04 
Hypertrophic cardiomyopathy 5 2.92E-05 0,0022 
Dilated cardiomyopathy 5 2.99E-05 0,0027 
Tight junction 5 1.41E-04 0.015 
Pathways in cancer 6 2.03E-94 0.025 
p53 signaling pathway 4 3.16E-04 0.044 
TGF-beta signaling pathway 4 8.29E-04 0.128 
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DOWN-REGULATED       
GO-Terms Enrichment scores     
sarcomere 4.33     
muscle development 4.26     
glucose metabolic 3.33     
Calcium homeostasis 2.17     
KEGG Pathways Number of genes p-value FDR 
Glycolysis 6 4.72E-08 7.59E-07 
Insulin signaling pathway 6 4.13E-06 1.33E-04 
Calcium signaling pathway 5 4.60E-05 0.0022 
MAPK signaling pathway 5 6.76E-94 0.0434 
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Supplementary Table 1. Primers used for genomic DNA and RNA amplification   
      
Amplification Starting 
material 
Specie
s 
5' - 3' forward 5' - 3' reverse Size 
(nt) 
      
PCR for mutation 
screening 
     
ZAK exon 2* genomic DNA human CTTTCTGCAGATTTTGTGGAAG TAGGTCTCTTGCAGCCCTGT 298 
ZAK exon 3 genomic DNA human CTCTAGCCTGGACAACACAGC GTGACATCTGACAGTAACAC 326 
ZAK exon 4 genomic DNA human AGAAACCACACCATGGAAC CCATCAGCTGTGGAATTCTTAC 392 
ZAK exon 5 genomic DNA human TTTCTGCTCTTGAGTTCTTTGAA TGATGCTCATTTCTACATGCAA 234 
ZAK exon 6 genomic DNA human TTGAAGACAGAAATAGAAGTTTATG
G 
ATGGTTATGGAACCGAGAGG 277 
ZAK exon 7 genomic DNA human TTGTAACTGATAATCCCTTAATTAGC
C 
GTTCTCCAATGGTGCTGCTTTAGG 347 
ZAK exon 8 genomic DNA human CATGTTAGATAAGGTCTCAG CCATAAGCGTGAACTTAC 274 
ZAK exon 9 genomic DNA human GTACTGAACCTGACTTCTCCG CAGTGCCTGGCATATTCTAAG 647 
ZAK exon 10 first part genomic DNA human GCTCCCTAAACCTGAGTGATCTG CTTACACAAGGCAACAAGCTTG 498 
ZAK exon 10 second part genomic DNA human CTATGCTTGTAGTATCTACG CAGGACTGTCATTCAGATC 286 
ZAK exon 11 first part genomic DNA human CAGCTCCATAGGTTATGCTGCACC GAACGCTGCTTGAGTCCACAC 550 
ZAK exon 11 second part genomic DNA human CTCCTGTGTAGTGCCAAC GGTCATGTAAATGTGATTGGC 616 
ZAK exon 12 genomic DNA human GCTGAGAGCTGAAAGAGTG GACTTTCCTAAGGCCCAATC 235 
ZAK exons 13 + 14 genomic DNA human CACTGACCATGTGTGAATC GAGCCAAGATTGTGCCTTTGCAC 436 
ZAK exon 15 genomic DNA human CTACACTGCTTTGGACAATGAG CCAGGGTATGAATTCTCTCAGTG 574 
ZAK exon 16 genomic DNA human CACAATGCATCTCTAGGTG GGCGTCTTCAGCTGACTGAG 616 
ZAK exon 17 genomic DNA human CTCAAGGCTGCACTAACTGG GTTCACACAGCATAAGTAG 515 
ZAK exon 18 genomic DNA human GTGGGAGGCCATGACTAGCTG CTTCCCAACACGTTGTGAGAG 492 
ZAK exon 19 genomic DNA human CATATTTGGGCCAACTGTTCAG CTGCTACTCGAAGCTCAAAG 463 
ZAK exon 20 genomic DNA human TGCAGCTTTAGTGTGGCTTAAA ACCTGCTTAGAAAAGCTATGTAGT
T 
782 
      
RT-PCR on human cells      
ZAK exons 3 to 11 cDNA human CAGGCAGAAATACTCAGTGTCC GGTGTTGGACTGCTCTGTCA 741 
ZAK exons 9 to 11 cDNA human AAGCAGTTGCCCCAGAAGT GGTGTTGGACTGCTCTGTCA 315 
      
qRT-PCR on mouse cells      
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ZAK cDNA mouse TCCAGCTCAGAGGGCAAC TGCGCAGAGTGTCTAACCAT 73 
      
qRT-PCR on mouse tissues      
ZAK cDNA mouse CTCAAAGAACGGGAGAGACG TCTTGCAGAGAGAGGCAAGAG 90 
      
House keeping genes      
18S cDNA mouse GTAACCCGTTGAACCCCATT  CCATCCAATCGGTAGTAGCG 102 
GAPDH cDNA human TTTACATGTTCCAATATGATTCCA  CTCCATGGTGGTGAAGACG 188 
GAPDH cDNA mouse TTGTGATGGGTGTGAACCAC TTCAGCTCTGGGATGACCTT 553 
      
*exon 2 contains the ATG start site     
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Supplementary Table 2. Exome coverage metrics    
Sample ID Total read (bp) Read mapped 
(%) 
Mean coverage  %20X 
Family 1     
Patient I-1 470 149 014 95,2 253 93,5 
  Mother 78 223 218 85,8  72.8 81 
 Father 81 065 438 85,5 72.6 80,91 
Family 2     
Patient II-1 64 249 938 98.1 71.49 85.3 
Patient II-2 68 604 070 98.12 76.09 85.9 
Mother 48 867 324 98.43 49.08 81 
Family 3     
Patient III-1 134 337 788 81.58 52 83.5 
Patient III-2 154 121 034 89.74 73.2 86.7 
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Supp Table 3: List of genes representing significant 
changes in expression in patient II-1.  
Up-regulated genes log2FoldChange p-value 
MYH8 7.73 7.50E-57 
MYBPH 8.04 2.18E-56 
COMP 9.34 8.83E-53 
TNNT2 7.38 3.64E-48 
COL19A1 7.84 1.75E-43 
IGFN1 5.72 4.68E-36 
CDKN1A 5.27 9.14E-30 
LOXL4 5.11 1.51E-27 
SCD 4.98 2.44E-27 
LTK 6.49 2.93E-27 
PNMAL1 5.33 2.67E-25 
CHRNA1 4.71 3.18E-25 
ACTC1 4.41 4.56E-23 
C21orf7 4.51 1.53E-22 
UTS2R 6.05 7.62E-21 
ASPN 4.32 1.17E-20 
TMEM8C 8.25 1.17E-20 
THBS4 4.10 3.32E-20 
CCDC8 4.51 3.32E-20 
ARHGAP36 5.17 1.46E-19 
CDH1 8.11 2.19E-19 
IFITM10 5.42 4.72E-18 
HLA 4.26 7.57E-18 
ANKRD1 3.82 2.03E-17 
MYH3 3.74 6.60E-17 
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EDA2R 4.70 8.44E-17 
PTPRF 4.02 9.31E-17 
SOX11 6.40 4.30E-16 
PAMR1 4.03 7.90E-16 
CLSTN2 4.02 9.86E-16 
MLLT11 3.79 3.20E-15 
ERBB3 3.86 3.51E-15 
NCAM1 3.63 5.82E-15 
SFRP4 3.49 1.55E-14 
SFRP2 3.66 2.58E-14 
KRT80 7.53 9.69E-14 
POSTN 3.73 1.39E-13 
DCLK1 3.48 1.99E-13 
TNMD 5.09 2.49E-13 
SCN5A 4.97 2.67E-13 
PRUNE2 3.44 3.52E-13 
BCAS1 6.63 8.22E-13 
COL11A1 5.33 8.75E-13 
MXRA5 3.39 1.10E-12 
SLC47A2 4.97 3.19E-12 
RUNX1 3.43 3.96E-12 
ALDH3A1 5.27 7.37E-12 
IGJ 4.16 7.48E-12 
WBSCR17 3.71 7.59E-12 
GADD45A 3.34 1.21E-11 
MAP1A 3.17 1.94E-11 
BGN 3.11 2.36E-11 
IGSF1 4.43 2.61E-11 
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MYCL1 4.26 4.79E-11 
CHRND 3.05 5.01E-11 
TNFRSF21 3.21 7.31E-11 
PERP 3.42 8.55E-11 
LUM 2.99 8.99E-11 
AJUBA 3.70 1.46E-10 
ANGPTL4 3.74 1.85E-10 
HAP1 6.35 2.72E-10 
SAMD11 4.42 5.23E-10 
NGFR 3.44 5.63E-10 
CILP 2.85 5.99E-10 
NPNT 3.14 6.03E-10 
FST 3.44 7.11E-10 
COL1A1 2.75 1.94E-09 
MUSK 4.60 2.53E-09 
EPB41L3 2.87 3.43E-09 
MC1R 3.85 3.49E-09 
NNMT 2.85 4.53E-09 
TNC 3.06 6.33E-09 
PLCE1 2.86 8.31E-09 
C3 2.66 8.39E-09 
DACT1 2.95 1.23E-08 
EPB41L4B 3.51 1.28E-08 
WISP2 2.78 1.76E-08 
IL21R 4.88 1.82E-08 
FGF7 3.31 1.90E-08 
SNX7 3.00 2.53E-08 
ELN 2.66 2.53E-08 
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MYL4 3.15 2.66E-08 
TDO2 5.76 6.22E-08 
TMEM119 2.91 1.23E-07 
COL3A1 2.46 1.30E-07 
SCG2 4.53 1.30E-07 
VASH2 3.35 1.53E-07 
ST8SIA2 3.38 1.53E-07 
VMO1 4.81 1.65E-07 
LINC00163 6.21 1.77E-07 
COL14A1 2.58 2.07E-07 
KCNE1L 5.88 2.15E-07 
NQO1 2.59 2.44E-07 
IYD 7.46 2.84E-07 
AEBP1 2.48 2.84E-07 
CP 3.26 2.99E-07 
NEFM 3.38 2.99E-07 
LOC100130417 7.50 3.25E-07 
EGLN3 2.65 3.65E-07 
ATP8B4 3.36 3.87E-07 
DNAH11 4.80 4.27E-07 
TTC24 5.58 4.33E-07 
SVOP 5.07 4.92E-07 
PMAIP1 3.96 4.97E-07 
KIAA1324 4.37 7.54E-07 
FIBIN 2.80 7.81E-07 
XG 3.01 8.37E-07 
SMPD3 2.61 9.13E-07 
GPC3 2.61 1.10E-06 
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RGS2 2.71 1.16E-06 
GALNTL6 5.13 1.16E-06 
SFRP1 2.61 1.19E-06 
EFCAB7 2.84 1.19E-06 
LRRN3 3.16 1.34E-06 
SHD 3.27 1.70E-06 
KIF1A 4.01 1.98E-06 
SIGLEC1 2.60 2.13E-06 
ELAVL2 4.95 2.15E-06 
CBR1 2.43 2.26E-06 
DUSP4 3.27 2.33E-06 
ANTXR1 2.30 2.48E-06 
CCDC80 2.27 2.55E-06 
ARHGAP28 2.47 2.68E-06 
SLC24A2 3.94 2.88E-06 
PRELP 2.47 3.02E-06 
TMEM200A 3.56 3.04E-06 
GYG2 3.92 3.07E-06 
CBS 3.45 3.38E-06 
CHRNG 3.28 3.73E-06 
FLJ41484 3.38 3.94E-06 
PRSS12 3.27 4.34E-06 
LEP 4.14 4.44E-06 
MYH4 2.33 4.44E-06 
IGF2 2.69 5.25E-06 
C11orf92 3.23 6.11E-06 
STX1B 3.81 6.45E-06 
FAM83H 5.01 6.48E-06 
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PPM1E 6.37 6.48E-06 
RBP4 3.57 6.67E-06 
COL12A1 2.23 6.68E-06 
PTPRD 2.50 6.97E-06 
KLHL2 2.67 7.11E-06 
OTOF 4.30 7.20E-06 
DLEU2L 4.23 7.20E-06 
FAT1 2.35 7.46E-06 
KAZALD1 2.44 7.59E-06 
PLXNB2 2.26 8.21E-06 
FMOD 2.27 8.31E-06 
ADIPOQ 3.15 8.34E-06 
CDH11 2.63 1.02E-05 
OAS1 2.76 1.06E-05 
CRISPLD1 3.17 1.12E-05 
ITGA3 2.27 1.12E-05 
SSC5D 2.30 1.13E-05 
IFIT3 2.36 1.16E-05 
SSTR5 5.87 1.17E-05 
MS4A7 2.79 1.57E-05 
MED12L 4.40 1.81E-05 
NCS1 2.68 1.98E-05 
CHRNE 3.74 2.15E-05 
ECM2 2.30 2.23E-05 
NRCAM 3.43 2.28E-05 
PCDHGC3 2.28 2.56E-05 
SVEP1 2.43 2.56E-05 
CLIP3 2.46 2.68E-05 
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GPR153 2.72 2.77E-05 
CELSR1 3.23 2.78E-05 
CFH 2.09 2.98E-05 
SH3BP4 2.23 4.07E-05 
TNFAIP8L3 3.01 4.07E-05 
ETV5 2.42 4.16E-05 
COL22A1 3.95 4.16E-05 
TP53I3 2.42 4.58E-05 
COL1A2 2.09 5.00E-05 
PCDHB15 3.06 5.28E-05 
CHRDL1 2.06 5.29E-05 
LINC00475 6.95 5.39E-05 
TUBB6 2.18 5.66E-05 
IFIT2 2.38 5.89E-05 
OGN 2.29 6.84E-05 
LEPR 2.31 8.33E-05 
JAM3 2.10 8.33E-05 
AKR1C3 2.14 9.95E-05 
CELF6 2.55 0.00010193 
C2 2.70 0.00010669 
MX2 2.27 0.00011811 
EPHA3 2.46 0.00013395 
MAN1A1 2.11 0.00013413 
SLC16A9 2.46 0.00013722 
PTGFRN 2.07 0.00015406 
C1orf105 5.27 0.00018251 
GXYLT2 3.63 0.00019565 
VSTM4 2.03 0.00019667 
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CD163 2.35 0.00021501 
ITGA10 2.53 0.00022591 
SPON1 3.06 0.00022591 
CD209 3.20 0.00022591 
AFF3 2.23 0.00022641 
PLEKHA2 2.02 0.00022851 
PCDH18 2.12 0.0002297 
FOXI2 3.26 0.00025104 
IGF1 2.01 0.00025325 
SLC8A2 4.62 0.00025684 
RAB31 2.07 0.00028988 
ITGB8 3.67 0.00029546 
CUX2 5.18 0.00031331 
CMIP 2.08 0.00031331 
COL8A1 2.48 0.00033087 
CEBPA 2.06 0.0003317 
PSD2 3.90 0.0003474 
F13A1 2.55 0.00034792 
FAP 2.04 0.00038874 
NAIP 2.10 0.00041072 
LOC100505875 4.25 0.00041636 
LOX 2.31 0.00044706 
OMD 2.63 0.00045981 
OSMR 2.02 0.00047756 
ADAM12 4.14 0.00047808 
TCEAL7 2.46 0.00048198 
CD163L1 2.66 0.00052968 
VGLL3 2.09 0.00056424 
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SUSD4 2.58 0.00059474 
ITGAM 2.21 0.00059474 
DNMT3B 2.68 0.00060725 
NT5E 2.05 0.00063253 
B3GALT2 4.65 0.00065679 
MGC45800 4.06 0.00065679 
FPR3 2.61 0.00066569 
MYO1D 2.01 0.0006893 
MICALL2 2.29 0.00068978 
PVALB 2.43 0.00069056 
STAB1 2.03 0.0007031 
FAM174B 2.02 0.00071348 
DNM3OS 2.01 0.00074579 
PCDHB14 2.52 0.00075522 
KCNC4 2.24 0.00080201 
LOC730101 3.07 0.00081197 
RGL1 2.02 0.0008494 
PHLDA1 2.22 0.00091824 
FBLN1 2.02 0.00091824 
PLXNB3 2.70 0.001014 
VWA5A 2.01 0.00101972 
FXYD3 4.78 0.0010439 
SLC4A3 2.56 0.00106935 
COL10A1 5.79 0.0010718 
NOX4 2.78 0.00108933 
LOC643201 4.31 0.00120147 
PNPLA3 4.11 0.00120147 
FBLN7 2.44 0.00123605 
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PLP1 2.16 0.00125427 
BAI2 2.67 0.00138878 
EPHB3 2.66 0.00141304 
L1CAM 2.18 0.00152825 
TSPAN11 2.41 0.00153884 
CPNE8 2.10 0.00161959 
TMEM136 2.28 0.00162469 
PTGFR 2.38 0.00163114 
PRKAR2B 2.05 0.00166201 
KLF5 2.14 0.00168138 
C1R 2.13 0.00168689 
SLC9A9 2.09 0.00175567 
EPSTI1 2.62 0.0017607 
VCAM1 2.32 0.00203526 
LDLRAD3 2.18 0.00227074 
MSR1 2.99 0.00245483 
TP73 3.10 0.00258351 
ISG15 2.06 0.00259425 
FLJ44511 3.27 0.00277974 
PLEKHH2 2.04 0.00278483 
PCK1 4.65 0.00303318 
MFAP2 2.37 0.003038 
RASL11B 3.64 0.00305204 
ISM1 2.33 0.00310804 
FGF9 2.91 0.00330832 
IL34 2.11 0.00337632 
KERA 4.82 0.00355461 
EDIL3 2.57 0.00378208 
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CTXN3 2.44 0.00383626 
HERC5 2.26 0.00389028 
FDXR 2.02 0.00396393 
GDF15 4.82 0.00398314 
UAP1L1 2.07 0.00417003 
KIAA1755 2.13 0.00428405 
SMAD9 2.07 0.00450365 
ELL3 2.23 0.00457398 
ETV4 3.65 0.00457398 
CA1 6.34 0.00481892 
ODZ2 3.19 0.00485792 
FLJ35776 2.78 0.00503218 
CSDC2 2.57 0.00572197 
P4HA3 4.34 0.00588813 
NRXN2 2.05 0.00595654 
SLC44A5 2.11 0.00597312 
CD24 2.58 0.00666451 
OASL 3.06 0.00679612 
PALM2 2.48 0.00686385 
DERL3 2.81 0.0069118 
ITGA9 2.11 0.00747639 
ATP10A 2.15 0.0076502 
CMTM7 2.38 0.00765917 
FAM196A 4.98 0.00797263 
TACSTD2 3.72 0.00804352 
THBS2 2.13 0.00810184 
MGP 2.16 0.00810184 
CYP4F11 4.66 0.00814492 
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PHF21B 4.25 0.00841878 
FCRLA 5.42 0.00868028 
TPSD1 3.48 0.0092529 
RPRM 6.15 0.00926259 
SPATA18 2.25 0.0094324 
FAM82A1 2.00 0.00978601 
TFEC 3.30 0.01000423 
CTTNBP2 2.74 0.01107623 
TLL1 2.36 0.01122723 
TUSC5 2.71 0.0112935 
PTGIR 2.50 0.0115087 
SRRM4 3.10 0.01178584 
PCDHB16 2.12 0.01195768 
TRIM14 2.32 0.01195768 
MIR133B 2.10 0.01250576 
SAA1 4.04 0.01250576 
HS3ST2 4.19 0.01250576 
TMEM45A 2.73 0.01255514 
SLC2A1 2.21 0.01292036 
ENTPD7 2.16 0.01298636 
MPZ 2.27 0.01309515 
LOC339240 3.55 0.01317973 
TMEM63C 2.58 0.01332387 
SRGAP2P2 2.10 0.01349648 
STEAP1 3.69 0.01349648 
TMEM229B 2.51 0.01358815 
NBEAP1 5.26 0.01409487 
LPPR4 2.05 0.01417795 
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CCBE1 3.24 0.01429735 
PKHD1 4.31 0.01472585 
HR 2.17 0.01508944 
DRP2 3.09 0.01536189 
DGAT2 2.03 0.01546642 
IGLL5 2.50 0.01564526 
EFNA5 2.68 0.0170751 
LGR6 3.40 0.01758203 
LOC729970 2.90 0.01758203 
DPYSL5 3.34 0.01758203 
LOC100144604 3.10 0.01780007 
MTUS2 3.62 0.01835785 
HPGD 2.15 0.01851341 
C19orf81 4.79 0.01900312 
SOX8 2.16 0.01931875 
MMP11 2.38 0.01948026 
HGF 2.42 0.01972971 
ADAMTS2 2.39 0.02029642 
PNMA2 2.34 0.02043682 
FLJ43860 2.05 0.02123914 
SLC16A6 2.45 0.02233051 
AQP3 2.22 0.02325651 
PCDHB11 2.72 0.02359863 
GRIA1 3.00 0.02392326 
ROBO2 3.13 0.02398081 
MEX3A 3.63 0.02459305 
LEFTY2 2.60 0.02459776 
DCX 3.65 0.024822 
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MS4A4A 2.12 0.02526008 
CYSLTR1 2.76 0.02690216 
MCOLN3 2.16 0.027276 
FAM171A2 3.11 0.027276 
CBLN4 2.39 0.02801018 
MYBPHL 2.97 0.02871951 
SCHIP1 2.92 0.02936528 
REPS2 2.17 0.02938514 
COCH 2.16 0.02948623 
LACC1 2.10 0.02975131 
TMEM158 2.08 0.03174355 
CCR5 2.64 0.0317689 
SATB2 2.00 0.03309207 
NIPAL4 5.88 0.03409678 
KCNH3 3.02 0.03448311 
PACSIN1 2.80 0.03741606 
SLC29A4 2.35 0.03877988 
S100A14 5.84 0.03890051 
C17orf107 2.79 0.03890051 
CIT 2.02 0.04299333 
CNTNAP4 3.88 0.04431254 
SCIN 3.18 0.04472567 
TUBB3 2.77 0.04516504 
PCDHB10 2.23 0.04524878 
PPP2R2B 2.72 0.04555892 
CDKN2A 4.29 0.04630238 
LOC284080 3.05 0.04838459 
POU4F1 2.59 0.04881969 
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CACNG8 2.13 0.049004 
LILRB5 2.14 0.049004 
IRF6 2.07 0.04900845 
LOC344887 4.54 0.04909107 
DIRAS1 2.56 0.04992266 
   Down-regulated genes 
  SLC16A3 -3.94 1.51E-11 
ZAK -3.58 4.17E-10 
G0S2 -3.40 2.85E-09 
MLF1 -3.41 8.01E-09 
MFAP3L -3.62 1.91E-08 
FAM166B -3.24 4.21E-08 
CALML6 -3.15 6.03E-08 
TUBA8 -3.06 1.47E-07 
ADSSL1 -2.90 3.69E-07 
DHRS7C -2.93 4.78E-07 
RPL3L -2.85 6.26E-07 
KIAA1161 -2.89 7.39E-07 
PPM1J -2.92 1.34E-06 
LOC284581 -4.63 1.39E-06 
PPP1R1A -2.77 1.42E-06 
UGT3A1 -3.63 2.27E-06 
LOC654433 -4.80 5.21E-06 
MID1IP1 -2.64 5.69E-06 
C3orf43 -2.64 7.90E-06 
CD38 -3.68 8.98E-06 
HIST1H1C -2.66 1.03E-05 
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KLHL38 -2.83 1.03E-05 
NKAIN1 -2.98 1.14E-05 
ODF3L2 -3.23 1.15E-05 
PEBP4 -2.40 4.58E-05 
GMPR -2.38 5.35E-05 
LOC653513 -2.49 5.82E-05 
CMYA5 -2.33 5.84E-05 
SLC38A3 -2.49 5.90E-05 
PPP1R3A -2.35 6.00E-05 
MN1 -2.36 6.36E-05 
SNTA1 -2.34 6.69E-05 
GAPDH -2.31 6.72E-05 
PHTF2 -2.31 9.13E-05 
NEURL -2.34 9.29E-05 
MAPKAPK3 -2.31 9.53E-05 
LMCD1 -2.29 0.00010201 
ITGB6 -2.32 0.00011055 
GADL1 -2.43 0.00013395 
LOC100188947 -3.80 0.00013504 
PFKFB1 -2.30 0.00013975 
SBK1 -2.30 0.00016212 
NOS1 -2.71 0.00018251 
TBC1D1 -2.23 0.00021501 
PHKA1 -2.20 0.00022366 
PYGM -2.69 0.00023247 
FEM1A -2.16 0.00025688 
KBTBD12 -2.19 0.00027838 
CSRP3 -2.15 0.00028705 
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MYOZ3 -2.15 0.00028988 
TCAP -2.13 0.00029272 
TTN -2.12 0.00032369 
ALDOA -2.59 0.00032369 
THNSL2 -4.06 0.0003474 
FYCO1 -2.12 0.0003474 
DYRK1B -2.14 0.00035251 
KBTBD13 -2.33 0.0003592 
LGR5 -2.43 0.00036168 
MYLK4 -3.12 0.00038699 
PITX3 -2.43 0.00039484 
CHCHD10 -2.11 0.00043401 
FNDC5 -2.08 0.00050307 
ASB12 -2.22 0.00053962 
ATP2B2 -3.81 0.00056322 
SLC7A2 -2.07 0.00056424 
TTC40 -3.74 0.00056424 
RORC -2.11 0.00059669 
TMEM52 -2.07 0.00061076 
HDAC11 -2.17 0.00061076 
EEF1A2 -2.04 0.00062296 
JPH1 -2.04 0.00064118 
PGM1 -2.35 0.00074579 
PWWP2B -2.26 0.00085449 
FLJ41941 -2.17 0.0008785 
C1orf127 -3.26 0.00091824 
ASB10 -2.06 0.00099231 
GPR157 -2.42 0.00106137 
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HRASLS -2.19 0.00108179 
C11orf67 -2.04 0.00110128 
ST3GAL3 -2.02 0.00123804 
CA2 -2.09 0.00134805 
GYPC -2.06 0.00137911 
PITX1 -2.08 0.00142548 
RXRG -2.01 0.00168689 
MAP2K6 -2.29 0.00169643 
RNF128 -2.59 0.00209349 
FHL3 -2.90 0.00211464 
ALDH1L1 -2.86 0.00216046 
CITED4 -2.05 0.00295922 
BZRAP1 -2.08 0.00303318 
HIST1H2BD -2.59 0.00309523 
NUDT8 -2.14 0.00349955 
KLKB1 -3.34 0.00360345 
HEXIM2 -2.19 0.00372426 
MGC14436 -3.93 0.00428531 
C14orf180 -2.23 0.00429454 
FCGR3B -3.50 0.00559617 
ATP13A5 -2.77 0.00559617 
GADD45G -3.13 0.00597885 
COX7A1 -2.05 0.006138 
MYH2 -3.42 0.00622402 
NEK10 -3.01 0.00654176 
PPP1R3C -2.55 0.0077606 
FLNC -2.00 0.00803538 
CA14 -4.09 0.00978601 
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DNAJB5 -2.94 0.01266959 
DAAM2 -2.08 0.01472585 
ACTA1 -2.70 0.01799528 
LRRC20 -2.55 0.01908611 
CHDH -2.08 0.02036383 
PGAM2 -3.01 0.02087271 
NRG4 -2.19 0.02147441 
C15orf27 -3.08 0.0254238 
KCNJ12 -2.86 0.02561539 
LOC100505894 -2.17 0.02872335 
FBP2 -3.48 0.02948623 
AGBL1 -2.55 0.03095983 
INPP5J -2.36 0.03441661 
SYNPO -2.53 0.03673402 
ASB2 -2.06 0.03754675 
ENO3 -3.02 0.0428011 
RET -2.37 0.04476153 
CNGA1 -2.39 0.04625446 
CXCR1 -4.33 0.04916442 
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